Small Cap Biotechs

For Biotech and Pharmaceutical Companies

Looking for Financing, PR or Investor Relations Services?

We facilitate introductions to leading hedge funds who share your company's best interests and may be interested in investing in you. We also bump shoulders with some of the premier Investor Relations & PR firms in the United States. We've a track record of success which supports these relationships, and a network that feeds our success. If you have a company in need of greater visibility or capital investment, we'd like to hear from you.

Biotech News and Updates

Sientra (NASDAQ: SIEN) : DD and More

December 13, 2015

Comments Off

A few excerpts:

PennyStockHaven:

From Sientra’s (SIEN) 8-K filing from October 30th, 2015:
We continue to be well funded with a cash and cash equivalents balance of $148.9 million as of September 30, 2015. Earlier

SANUWAVE (SNWV): U.S. Patent to Sterilize Blood Using SNWV’s Shock Wave Technology

April 11, 2013

Comments Off

SANUWAVE Health, Inc. (OTCBB:SNWV) has received a patent issued by the U.S. Patent and Trademark Office entitled “Method and Devices for Cleaning and Sterilization with Shock Waves.” The claims of the patent (patent number 8,343,420) relate to a new method that sterilizes

BioCryst Pharmaceuticals (BCRX): Update Regarding Peramivir

April 1, 2013

Comments Off

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and inflammatory diseases.

BioCryst announced that it received a preliminary comment letter from the FDA that

Cell Therapeutics, Inc.(CTIC): $15MM Loan Financing Agreement

March 28, 2013

Comments Off

Cell Therapeutics, Inc. (CTIC) announced that it has entered into a Loan and Security Agreement with Hercules Technology Growth Capital, Inc. for a senior secured term loan of up to $15 million. The first

AntriaBio (ANTB): An Opportunity

March 17, 2013

Comments Off

Novo Nordisk – the world ‘s largest insulin producer – and major diabetes drug manufacturers – could see BILLIONS in recurring revenue dry up as a small, California-based biotech company advances a technology that promises to change diabetes treatment.

Over $100,000,000 has been invested in developing this super-drug that threatens to make products like Sanofi’ s $6 BILLION-A-YEAR basal insulin – ‘Lantus’ – OBSOLETE.

The Company that ‘s making executives in the world’ s largest pharmaceutical firms sweat is Menlo Park, California-based ANTRIABIO, INC. (ANTB)

Here ‘s why large pharma is worried about ANTRIABIO’ s technology:

Basal

Oncolytics Biotech (ONCY): Positive REOLSYIN Clinical Trial Data from Phase 2 Study

February 8, 2013

Comments Off

Oncolytics Biotech Inc. (NASDAQ: ONCY) is focused on the development of oncolytic viruses for use as cancer therapeutics. The Company’s lead product, REOLYSIN®, a proprietary formulation of the human reovirus, is currently in late stage

Market Overlooking Eventful Upcoming 12 Months for Spring Bank (SBPH)
Fri, Mar 15
Spring Bank provided a business update earlier this week to discuss 2019 development plant for their · more »
Fennec Delays NDA Due to Manufacturing Facility Change
Wed, Mar 13
Fennec announced some bad news this morning. Their NDA submission for Pedmark has been pushed back by · more »
Aldeyra Shares Details On Phase 3 Pipeline Candidates
Thu, Feb 28
This morning, Aldeyra hosted their RD day, where they discussed their pipeline and upcoming plans. · more »
The Street is Finally Starting to Pick Up on Bellus’ Story
Tue, Feb 19
It seems the market is starting to realize Bellus’ potential as the company touched a 52 week high · more »
Fennec’s $12.5M Loan Gives Company Viable Alternative To Commercialize Alone
Mon, Feb 4
Today Fennec (FENC) announced a $12.5 million senior loan with the Life Sciences Group at Bridge Bank. · more »
Aldeyra’s All Stock Deal Could Be Sign Of Validation
Tue, Jan 29
Today, Aldeyra (ALDX) acquired privately company Helio Vision for an all stock deal worth $12.5M, with · more »
Overlooked Name Could Be A Pillar To Cure of Multi-Billion Dollar Disease
Sat, Jan 26
SBPH is developing inarigivir, an immune activator that boosts the efficacy of the immune system · more »
Aldeyra’s Enrollment Numbers Could Be Key Difference in Phase 3 Allergic Conjunctivitis
Thu, Jan 3
Aldeyra (ALDX) will be reporting results from their first Phase 3 study in allergic conjunctivitis · more »
Broad NDA Announcement is Large De-Risking Event for Fennec
Thu, Dec 20
Today Fennec (FENC) announced that the company initiated its rolling NDA for chemo induced hearing · more »

Recent Updates

For Biotech and Pharmaceutical Companies

Looking for Financing, PR or Investor Relations Services?

Biotech News and Updates

Sientra (NASDAQ: SIEN) : DD and More

SANUWAVE (SNWV): U.S. Patent to Sterilize Blood Using SNWV’s Shock Wave Technology

BioCryst Pharmaceuticals (BCRX): Update Regarding Peramivir

Cell Therapeutics, Inc.(CTIC): $15MM Loan Financing Agreement

AntriaBio (ANTB): An Opportunity

Oncolytics Biotech (ONCY): Positive REOLSYIN Clinical Trial Data from Phase 2 Study

Biotech Stocks Reviews